Showing results (121-130 of 198) with videos related to

Sort By:
Pageof 20
JACC. Advances|July 23, 2026
Outcomes With Warfarin in Atrial Fibrillation: Individual Patient Data Analysis From Four Randomized TrialsSamer Al Said, Eugene Braunwald, Elaine M Hylek, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Circulation|January 30, 2026
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus WarfarinSamer Al Said, Eugene Braunwald, Michael G Palazzolo, et al.
American Journal of Epidemiology|October 9, 2025
Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trialsRobert Thiesmeier, Paul M Haller, Siddharth M Patel, et al.
JACC. Advances|July 23, 2026
Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial FibrillationSamer Al Said, Andrea Bellavia, Eugene Braunwald, et al.
Journal of the American Heart Association|October 28, 2025
Contemporary Practice Patterns of Vasoactive Use in Cardiogenic Shock in the American Heart Association Cardiogenic Shock RegistrySiddharth M Patel, David D Berg, Erin A Bohula, et al.
JAMA Cardiology|November 13, 2021
Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and ContentNicholas A Marston, Robert P Giugliano, Giorgio E M Melloni, et al.
Journal of the American College of Cardiology|March 19, 2025
Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial FibrillationLars Wallentin, Johan Lindbäck, Ziad Hijazi, et al.
Circulation|November 12, 2019
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER TrialNicholas A Marston, Frederick K Kamanu, Francesco Nordio, et al.
Stroke|June 21, 2014
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48Robert P Giugliano, Christian T Ruff, Natalia S Rost, et al.
Pageof 20